These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30984817)

  • 1. No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model.
    Baakman AC; Alvarez-Jimenez R; Loewen G; de Kam ML; Broekhuizen K; Hilt DC; Groeneveld GJ
    Alzheimers Dement (N Y); 2019; 5():89-98. PubMed ID: 30984817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor.
    Snyder PJ; Bednar MM; Cromer JR; Maruff P
    Alzheimers Dement; 2005 Oct; 1(2):126-35. PubMed ID: 19595845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans.
    Cho W; Maruff P; Connell J; Gargano C; Calder N; Doran S; Fox-Bosetti S; Hassan A; Renger J; Herman G; Lines C; Verma A
    Psychopharmacology (Berl); 2011 Dec; 218(3):513-24. PubMed ID: 21644059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning.
    Weed MR; Polino J; Signor L; Bookbinder M; Keavy D; Benitex Y; Morgan DG; King D; Macor JE; Zaczek R; Olson R; Bristow LJ
    PLoS One; 2017; 12(12):e0187609. PubMed ID: 29261656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scopolamine disrupts place navigation in rats and humans: a translational validation of the Hidden Goal Task in the Morris water maze and a real maze for humans.
    Laczó J; Markova H; Lobellova V; Gazova I; Parizkova M; Cerman J; Nekovarova T; Vales K; Klovrzova S; Harrison J; Windisch M; Vlcek K; Svoboda J; Hort J; Stuchlik A
    Psychopharmacology (Berl); 2017 Feb; 234(4):535-547. PubMed ID: 27885411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
    Prickaerts J; van Goethem NP; Chesworth R; Shapiro G; Boess FG; Methfessel C; Reneerkens OA; Flood DG; Hilt D; Gawryl M; Bertrand S; Bertrand D; König G
    Neuropharmacology; 2012 Feb; 62(2):1099-110. PubMed ID: 22085888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cholinergic neurotransmission modulation on visual spatial paired associate learning in healthy human adults.
    Harel BT; Pietrzak RH; Snyder PJ; Maruff P
    Psychopharmacology (Berl); 2013 Aug; 228(4):673-83. PubMed ID: 23568575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.
    de Bruin NM; Prickaerts J; van Loevezijn A; Venhorst J; de Groote L; Houba P; Reneerkens O; Akkerman S; Kruse CG
    Neurobiol Learn Mem; 2011 Sep; 96(2):392-402. PubMed ID: 21757018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product.
    Sadhu A; Upadhyay P; Agrawal A; Ilango K; Karmakar D; Singh GP; Dubey GP
    Clin Drug Investig; 2014 Dec; 34(12):857-69. PubMed ID: 25316430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.
    Deardorff WJ; Shobassy A; Grossberg GT
    Expert Rev Neurother; 2015 Jan; 15(1):7-17. PubMed ID: 25495510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Pharmacokinetics of HTL0018318, a Novel M
    Bakker C; van der Aart J; Labots G; Liptrot J; Cross DM; Klaassen ES; Dickinson S; Tasker T; Groeneveld GJ
    Drugs R D; 2021 Sep; 21(3):295-304. PubMed ID: 34164794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procognitive effect of AC-3933 in aged mice, and synergistic effect of combination with donepezil in scopolamine-treated mice.
    Hashimoto T; Hatayama Y; Nakamichi K; Yoshida N
    Eur J Pharmacol; 2014 Dec; 745():123-8. PubMed ID: 25446931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
    Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
    Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
    Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
    Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study.
    Kim KA; Lim JL; Kim C; Park JY
    Clin Ther; 2011 Jul; 33(7):965-72. PubMed ID: 21723605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
    Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
    Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.